• 1 Overview
  • 1.1 Objectives
  • 1.2 Scope
  • 1.3 Methodology
  • 1.4 Executive Summary
• 2 Rna Interference (Rnai)
  • 2.1 Introduction
  • 2.2 Overview Of Rna Interference
    • 2.2.1 Classes Of Endogenous Small Rnas: Sirna, Rasirna And Mirna
    • 2.2.2 Mechanism Of Rnai In Vivo
  • 2.3 Glossary
  • 2.4 What Areas Of Research Does Rnai Impact?
    • 2.4.1 Rnai Technology In Life Sciences Research, Drug Discovery And Development
    • 2.4.2 Rnai Technology In Agriculture
• 3 Technology Trends In Rnai Space
  • 3.1 Overview
  • 3.2 End-User Segmentation
  • 3.3 Technologies For Inducing Rnai
    • 3.3.1 Methods For Detecting Gene Silencing
    • 3.3.2 Comparison Of Strategies For Target Validation
    • 3.3.3 Libraries Of Sirnas/Shrnas To Knock Down Genes En Masse
  • 3.4 Mirna-Based Rnai: The Leading Edge Of Rnai Space
    • 3.4.1 Biological Function Of Mirnas
    • 3.4.2 Role Of Mirnas In Disease
    • 3.4.3 Mirna-Based Diagnostics
    • 3.4.4 Mirna-Based Therapeutics
  • 3.5 Market Shifts In Rnai Space: Where Is It Headed?
    • 3.5.1 Intellectual Property And Patent Issues
    • 3.5.2 Patents Covering The Molecular Characteristics Of The Rnai Agent
    • 3.5.3 Funding In Rnai Space: Grants, Venture Capital And Ipos
    • 3.5.4 Partnerships, Alliances, Mergers And Acquisitions
  • 3.6 Swot Analysis Of Technologies And Vendors In Rnai Space
• 4 Rnai Market Analysis
  • 4.1 Overview
  • 4.2 Market Data Collection And Respondent Pool
    • 4.2.1 Respondent Pool Characteristics
  • 4.3 Rnai Technologies / Products In Research Applications
  • 4.4 Rnai Technologies/Products: Market Shares (Quantitative)
  • 4.5 Quantitative Metrics Of Rnai Usage: Market Opportunity And Growth
    • 4.5.1 Growth Of Various Segments In Rnai Space
    • 4.5.2 Product Formats And Representation In Rnai Marketplace
  • 4.6 Rnai Marketplace: Challenges, Unmet Needs And Drivers
    • 4.6.1 Unmet Needs In Rnai Space
    • 4.6.2 Rnai Market: Qualitative Growth Drivers
• 5 The Rnai Landscape
  • 5.1 Overview
  • 5.2 Market Segmentation Of Rnai And Segment Characteristics
  • 5.3 Quantitative Market Opportunities In Rnai Space
    • 5.3.1 Opportunities In Mirna Space
    • 5.3.2 Opportunities In Sirna/Shrna Space
  • 5.4 Rnai Product Offerings And Associated Business Models
  • 5.5 Challenges For Rnai Therapeutic Development
• 6 Rnai-Based Therapeutics: The Emerging Industry Landscape
  • 6.1 Factors Contributing To The Success Of Rnai Therapeutics
  • 6.2 Advantages And Disadvantages Of Sirna-Based Drugs
  • 6.3 Opportunities And Challenges With Rnai-Based Therapeutics
  • 6.4 The Gene Therapy Precedent
  • 6.5 The Antisense Precedent
  • 6.6 Interferon Response
  • 6.7 Delivery Of Rnai-Based Therapeutics
  • 6.8 Off-Target Effects
  • 6.9 Overwhelming The Endogenous Rnai System-affecting The Microrna Pathway
  • 6.10 Rnai-Based Therapeutics
    • 6.10.1 Cancer
    • 6.10.2 Cardiac Disease
    • 6.10.3 Immunologic Disease
    • 6.10.4 Infectious Disease
    • 6.10.5 Inflammation
    • 6.10.6 Lifestyle Therapeutics
    • 6.10.7 Metabolic Disease
    • 6.10.8 Neurologic Disease
    • 6.10.9 Ophthalmic Disease
    • 6.10.10 Renal Disease
    • 6.10.11 Respiratory Disease
• 7 Company Profiles-u.S
  • 7.1 Alfacell Corporation
  • 7.2 Allele Biotechnology And Pharmaceuticals, Inc
  • 7.3 Alnylam Pharmaceuticals
  • 7.4 Ambion
  • 7.5 Asuragen, Inc
  • 7.6 Avalon Pharmaceuticals, Inc
  • 7.7 B-Bridge International, Inc
  • 7.8 Bio-Rad Laboratories
  • 7.9 Calando Pharmaceuticals, Inc
  • 7.10 Cepheid
  • 7.11 Cequent
  • 7.12 Clontech Laboratories, Inc
  • 7.13 Combimatrix Corporation
  • 7.14 Cyntellect, Inc
  • 7.15 Cytrx Corp
  • 7.16 Dharmacon
  • 7.17 Dicerna
  • 7.18 Galenea Corporation
  • 7.19 Genecopoeia, Inc
  • 7.20 Genethera, Inc
  • 7.21 Genlantis
  • 7.22 Genosensor
  • 7.23 Grl, Inc
  • 7.24 Idt
  • 7.25 Imgenex Corporation
  • 7.26 Ingenuity Systems
  • 7.27 Intradigm Corporation
  • 7.28 Invitrogen
  • 7.29 Invivogen
  • 7.30 Isis Pharmaceuticals, Llc
  • 7.31 Lc Sciences
  • 7.32 Lentigen Corporation
  • 7.33 Merck & Co., Inc
  • 7.34 Mirus Bio Corporation (Acquired By Roche)
  • 7.35 Monsanto
  • 7.36 Nastech Pharmaceutical Company, Inc
  • 7.37 New England Biolabs
  • 7.38 Nucleonics, Inc
  • 7.39 Open Biosystems, Inc
  • 7.40 Opko Health, Inc
  • 7.41 Origene
  • 7.42 Panomics, Inc
  • 7.43 Phaserx
  • 7.44 Promega Corp
  • 7.45 Quark Pharmaceuticals, Inc
  • 7.46 Rxi Pharmaceuticals Corporation
  • 7.47 Senetek Plc
  • 7.48 Sigma-Aldrich
  • 7.49 Sirna Therapeutics
  • 7.50 Sirnaomics, Inc
  • 7.51 Somagenics, Inc
  • 7.52 System Biosciences
  • 7.53 Tacere Therapeutics
  • 7.54 Targeted Genetics Corporation
  • 7.55 Third Wave Technologies
  • 7.56 Traversa
• 8 Company Profiles-europe
  • 8.1 Actigenics Sa
  • 8.2 Amaxa
  • 8.3 Astrazeneca Plc
  • 8.4 Cenix Bioscience Gmbh
  • 8.5 Devgen N.V
  • 8.6 Dnavision
  • 8.7 Exiqon
  • 8.8 Genovis
  • 8.9 Genoway
  • 8.10 Imagenes Gmbh
  • 8.11 Mwg Biotech Ag
  • 8.12 Oz Biosciences
  • 8.13 Prosensa Holding
  • 8.14 Qiagen
  • 8.15 Rnax Gmbh (Germany)
  • 8.16 Roche
  • 8.17 Rosetta Genomics, Ltd
  • 8.18 Santaris Pharma A/S
  • 8.19 Silence Therapeutics Plc
  • 8.20 Taconicartemis Gmbh
  • 8.21 Transat
• 9 Company Profiles-asia-Pacific
  • 9.1 Alphagen Co., Ltd
  • 9.2 Benitec, Ltd
  • 9.3 Bioneer
  • 9.4 Cytopathfinder, Inc
  • 9.5 Genesis Research & Development Corp
  • 9.6 Genedesign, Inc
  • 9.7 Gni Pharmaceutical Corporation
  • 9.8 Koken Co., Ltd
  • 9.9 Nanocarrier Co., Ltd
  • 9.10 Oncolys Biopharma, Inc
  • 9.11 Realgene Bio-Technologies, Inc
  • 9.12 Samchully Pharmaceuticals
  • 9.13 Samyang Corp
  • 9.14 Shanghai Biochip
  • 9.15 Shanghai Genepharma Co
  • 9.16 Shanghai Genomics, Inc
  • 9.17 Transgene Biotek, Ltd
• 10 Company Profiles-rest Of The World
  • 10.1 Benitec, Ltd
  • 10.2 Tekmira
• Index Of Tables
  • Table 2.1: Advantages/Disadvantages Of Sirnas And Shrnas As Inducers Of Rnai In Mammalian Cells
  • Table 2.2: Prevalence Of Sirna-Mediated Rnai In Disease Models, As Reported In Scientific Literature
  • Table 2.3: Rnai-Based Therapeutics In Clinical Trials
  • Table 2.4: Suppliers Of Enabling Technologies And Tools In Rnai Space
  • Table 2.5: Suppliers Of Sirna/Shrna Products (By Product/Service Class)
  • Table 3.1: Currently-Utilized Technologies For Inducing Rnai-Mediated Knockdown
  • Table 3.2: Comparison Of Mrna Detection Technologies
  • Table 3.3: Strategies For Target Validation By Pharma/Biotech: Rnai And Others
  • Table 3.4: Comparison Of Formats For Library-Based Gene Knockdown
  • Table 3.5: Characteristics Of Various Publicly-Available Mouse And Human Rnai Libraries
  • Table 3.6: Disease-Related Mirnas
  • Table 3.7: Publicly-Available Computational Programs For Identifying Mirna Sequences/Targets
  • Table 3.8: Seminal Patents In Rnai
  • Table 3.9: Venture Capital Raised By Selected Companies In The Rnai Space
  • Table 3.10: List Of Public Biotech Companies In Rnai Space
  • Table 3.11: Swot Analysis Of Sirna Oligonucleotides
  • Table 3.12: Transfection Reagents (Lipid-Mediated Delivery)
  • Table 3.13: Shrna Plasmid Constructs
  • Table 3.14: Shrna Pooled Libraries Or Arrayed Collections (Retroviral/Lentiviral Delivery)
  • Table 5.1: Rnai Market Segmentation And Research Settings
  • Table 5.2: Segment 1: Basic Life Science Research Utilizing Rnai Tools And Technologies
  • Table 5.3: Segment 2: Rnai For Drug Discovery And Development
  • Table 5.4: Segment 3: Rnai Research For Development Of Rnai Therapeutics
  • Table 5.5: Segment 4: Rnai Fee-For-Service Business
  • Table 5.6: Grants Awarded And Research Spending In Mirna Space, 2005 To 2008
  • Table 5.7: Rnai Opportunity And Market Size: Quantitative Model, 2006 To 2009
  • Table 5.8: Challenges For Rnai Therapeutic Development
  • Table 5.9: Technology Platforms Used In Rnai Research
  • Table 6.1 : Similarities Between Antisense Oligonucleotides And Sirnas
  • Table 6.2: Disadvantages Of Sirna Versus Antisense Oligonucleotides
  • Table 6.3: Delivery Vectors For Sirna And Hairpin-Encoding Dna For In Vivo Experiments
  • Table 6.4: Delivery Systems For Sirna And Hairpin-Encoding Dna For In Vivo Experiments
  • Table 6.5: Delivery Systems For Rnai-Based Therapeutics
  • Table 6.6: Diseases For Rnai Therapeutics
  • Table 6.7: Rnai-Based Therapeutics Pipeline-broken Out By Disease/Therapeutic Area
  • Table 6.8: Rnai-Based Therapeutics Pipeline-broken Out By Stage Of Development
  • Table 6.9: Most Common Types Of Cancer
  • Table 6.10: Rnai Therapeutics For Cancer In Phase I
  • Table 6.11: Rnai Therapeutics For Cancer In Ind
  • Table 6.12: Rnai Therapeutics For Cardiac Disease In Ind
  • Table 6.13: Rnai Therapeutics For Cardiac Disease In Pre-Clinical/Research
  • Table 6.14: Rnai Therapeutics For Immunologic Disease In Pre-Clinical / Research
  • Table 6.15: Rnai Therapeutics For Infectious Disease In Phase Ii
  • Table 6.16: Rnai Therapeutics For Infectious Disease In Phase I
  • Table 6.17: Rnai Therapeutics For Infectious Disease In Ind
  • Table 6.18: Rnai Therapeutics For Infectious Disease In Pre-Clinical/Research
  • Table 6.19: Rnai Therapeutics For Inflammatory Disease In Pre-Clinical/Research
  • Table 6.20: Rnai Therapeutics For Life Style Therapies In Ind
  • Table 6.21: Rnai Therapeutics For Metabolic Disease In Pre-Clinical/Research
  • Table 6.22: Rnai Therapeutics For Neurologic Disease In Pre-Clinical/Research
  • Table 6.23: Rnai Therapeutics For Ophthalmic Disease In Phase Iii
  • Table 6.24: Rnai Therapeutics For Ophthalmic Disease In Phase Ii
  • Table 6.25: Rnai Therapeutics For Ophthalmic Disease In Phase I
  • Table 6.26: Rnai Therapeutics For Ophthalmic Disease In Pre-Clinical/Research
  • Table 6.27: Rnai Therapeutics For Renal Disease In Phase I
  • Table 6.28: Rnai Therapeutics For Respiratory Disease In Pre-Clinical/Research
  • Table 10.1: Nucleonics Products And Programs Ongoing/Pipeline
  • Table 10.2: Quark''s Product Pipeline
  • Table 10.3: Santaris'' Product Pipeline
  • Table 10.4: Silence Therapeutics'' Product Pipeline
• Figure 2.1: The Mirna Processing Pathway
• Figure 2.2: Growth Of Scientific Publications Addressing Mirnas, 2001 To 2008
• Figure 2.3: Mechanisms Of Small Rna-Induced Gene Regulation
• Figure 2.4: Types Of Rnai Compounds
• Figure 2.5: Breakdown Of Scientific Publications Related To Rnai By Geographic Region, 2007 To 2008
• Figure 3.1: End-User Segmentation Of Rnai Space
• Figure 3.2: Rnai Patents Filed Globally, By Geographical Origin
• Figure 3.3: Selected Deals In Rnai Space
• Figure 4.1: Geographical Breakdown Of Rnai End-User Survey Respondents
• Figure 4.2: Affiliation Of Rnai End-User Survey Respondents
• Figure 4.3: Utilization Of Rnai Technologies/Products By Respondent Pool
• Figure 4.4: Rnai Utilization Period: Breakdown Of Respondent Pool
• Figure 4.5: Research Applications Using Rnai Technologies/Products
• Figure 4.6: Types Of Rnai Technologies Currently Utilized
• Figure 4.7: Rnai Technologies Most Commonly Utilized Currently By End-Users
• Figure 4.8: Types Of Rnai Technologies: Expected Use In Six To 18 Months
• Figure 4.9: Evolution Of Market Shares Of Rnai-Inducing Technologies
• Figure 4.10: Number Of Experiments Involving Rnai Conducted Per Week
• Figure 4.11: Range Of Research Dollars Spent Monthly On Rnai Research
• Figure 4.12: Rnai Experiment Throughput Correlated With Type Of Rnai Technology Used
• Figure 4.13: Current Rnai Market Share By Segments
• Figure 4.14: Growth/Decline Rate Of Rnai Marketplace Segments (Six To 18 Months)
• Figure 4.15: Product Formats Utilization For Rnai Research (Current And Six To 18 Months)
• Figure 4.16: Companies Offering Product Formats For Currently-Used Rnai Products
• Figure 4.17: Rnai Product Offerings/Formats Use (Projections-six To 18 Months)
• Figure 4.18: Percentage Change Of Rnai Product Offerings/Formats (Six To 18 Months)
• Figure 4.19: Key Challenges Faced By End-Users In Rnai Space
• Figure 4.20: Unmet Needs In Rnai Space Ranked By Importance To End-Users
• Figure 5.1: Growth And Evolution Of Mirna Space
• Figure 5.2: Elements Of Rnai Value Chain
• Figure 5.3: Growth And Evolution Of Rnai (Sirna/Shrna) Space
• Figure 5.4: Market Revenues Based On Components Of Sirna Experimental Paradigm

Buy now >>